source
- Roivant Sciences launches first solo drug, Lisraya, after FDA approval for dermatomyositisRoivant Sciences, which operates a hub-and-spoke subsidiary model, is stepping into the commercial arena with its inaugural solo product launch. The FDA has granted approval to the oral TYK2/JAK i…
- CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potentialCSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…